alpha biomed glp 1 Dr. Gal | Functional Medicine A science Peptides – Shores Dental Co.

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021

Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies

Schedule a free consultation with our Clinic Director 2

Violante S, Ijlst L, Te Brinke H, Koster J, Tavares de Almeida I, Wanders RJA, et al

This combination is frequently prescribed for individuals recovery from illness, those with diabetic neuropathy, or patients with fatigue related to specific nutritional gaps

Safety and Pharmacology Evaluations : Conducting preclinical toxicology, pharmacokinetic, and receptor-binding studies to characterize how AOD 9604 is handled in vivo and confirm it does not activate growth hormone-like proliferative pathways